看多
Possible H&S, after FDA approval for fast track consideration?
The MACD and RSI looks a little overbought. Also the upcoming FDA approval, is not for usage of the drug. But just a Phase 3 fast track evaluation of the drug. Which would take another few months, before an actual approval.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
註釋
Looks like not much chance of a major correction, with more institutional investors coming in.註釋
Seems like a correction till 2.20
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。